GLP-1s and Eating Disorders: A Cautious Look

GLP-1 medications suppress appetite. That is the entire point of the drug, and for many people it is helpful. But appetite suppression sits at the center of eating disorders, which makes the intersection of these drugs and disordered eating a place where caution is not optional. This is a topic where the honest answer is that we know less than we should.

Why the overlap is delicate

Eating disorders are not just about eating too little or too much; they involve a disturbed relationship with food, body image, and control. A medication that powerfully reduces hunger and shrinks how much someone eats can interact with that psychology in ways that are hard to predict and harder to study.

A drug that makes it easier to eat less is a different proposition for someone who already restricts food than for someone who struggles to feel full. The same mechanism can help one person and harm another.

The concern runs in more than one direction. For someone with a restrictive eating disorder, the appetite suppression could reinforce harmful patterns. For binge-eating disorder, by contrast, GLP-1 effects on appetite and reward have generated real interest as a potential aid, though the evidence there is preliminary.

What the binge-eating evidence is

Berries, full hd wallpaper, fruits — illustrating GLP-1s and Eating Disorders: A Cautious Look

The most-cited supportive data is a 2023 retrospective, open-label cohort study published in Obesity Pillars. Among 98 patients, those treated with semaglutide showed a roughly 14-point drop on the Binge Eating Scale, larger than the comparison medications. Encouraging, but the design matters.

It was retrospective and open-label, not a randomized controlled trial; the authors themselves call for randomized studies.
A 2024 systematic review reached the same conclusion: methodological limits make firm efficacy claims premature.
Patients with active restrictive eating disorders are usually excluded from this research, so we have little safety data in exactly the group where appetite suppression is most concerning.

The candid summary: there is a genuine, plausible signal for binge-eating disorder, but it rests on small, non-randomized studies, and it is not a settled, approved indication.

The practical posture

Because the data are thin, responsible practice leans conservative. Screening for disordered eating before starting a GLP-1, and monitoring closely during treatment, is sensible even though the evidence base guiding it is incomplete. Major eating-disorder organizations note that benefit for binge eating remains unconfirmed and call for more research. This is an area to defer to qualified clinicians rather than self-experiment.

The takeaway

The appetite effects that make GLP-1s useful are exactly what make them sensitive in the context of eating disorders. The binge-eating signal is real but rests on retrospective, open-label data (promising, not proven), and the restrictive-disorder side carries genuine theoretical risk with almost no controlled evidence. The data suggest caution, individualized clinical judgment, and humility, not blanket reassurance and not blanket alarm.